Dr. Bruce Bloom, March 28, 2013Bruce E. Bloom Informal Headshot

Two of our favorite organizations in the Repurposing Revolution are getting together to drive drug repurposing to patients. DART Therapeutic, a biotechnology firm started by a group of Duchenne muscular dystrophy (DMD ) voluntary health organizations, and Biovista, a partner of ours and the leader drug repurposing opportunity discovery entered into a research collaboration to identify and develop drug repositioning candidates for DMD using Biovista's Clinical Outcome Search Space (COSS)â„¢ technology. We've used the COSS technology to help us find some drug repositioning opportunities for leukemia, and are working with BioVista on several other diseases.  Read more in this recent press release.

In addition, one the DMD projects in our Rediscovery Researchâ„¢ portfolio has just gotten funding approval. This project, proposed by Dr. Subha Raman of Ohio State University, will complete a randomized, controlled clinical trial repurposing a drug typically reserved for advanced heart failure to delay heart disease in DMD patients.